Michael Narachi
Direktor/Vorstandsmitglied bei ULTRAGENYX PHARMACEUTICAL INC.
Vermögen: 1 Mio $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Emil Kakkis | M | 63 | 14 Jahre | |
| Daniel Welch | M | 66 | 9 Jahre | |
| Matthew Busch | M | 50 | 20 Jahre | |
| Eric Crombez | M | - | 7 Jahre | |
| Robert Eckert | M | 69 | 21 Jahre | |
| Matthew Fust | M | 59 | 10 Jahre | |
| Amrit Ray | M | 51 | 2 Jahre | |
| Corazon Sanders | M | 67 | 3 Jahre | |
| Stephen J. Ubl | M | - |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | 9 Jahre |
| Deborah Dunsire | M | 61 | 7 Jahre | |
| Shehnaaz Suliman | M | 52 | 5 Jahre | |
| Joshua Higa | M | - | - | |
| Mike Zahigian | M | - | 23 Jahre | |
| Ernie Meyer | M | 60 | 4 Jahre | |
| Karah Parschauer | F | 46 | 8 Jahre | |
| Rodger Currie | M | - |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | 8 Jahre |
| Thomas Kassberg | M | 63 | 13 Jahre | |
| Dennis Huang | M | 59 | 9 Jahre | |
| Samuel Wadsworth | M | 75 | 7 Jahre | |
| Vimal Srivastava | M | 58 | 13 Jahre | |
| Erik Harris | M | 54 | 7 Jahre | |
| John Pinion | M | 58 | 9 Jahre | |
| Derek Miller | M | - | 21 Jahre | |
| Theodore Huizenga | M | 53 | 10 Jahre | |
| Howard Horn | M | 47 | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Frank Thomas | M | 54 | 6 Jahre | |
| Thomas P. Lynch | M | 57 | 3 Jahre | |
| Jerome Goldstein | M | 84 | 26 Jahre | |
| Paul Cleveland | M | 67 |
Celladon Corp.
 Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 1 Jahre |
| William Heiden | M | 64 |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | 8 Jahre |
| Graham Cooper | M | 54 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 9 Jahre |
| Eckard Weber | M | 73 | 14 Jahre | |
| Peter Honig | M | 67 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 8 Jahre |
| Scott A. Holmes | M | 50 | 4 Jahre | |
| Robin D. Campbell | M | 69 |
Naryx Pharma, Inc.
 Naryx Pharma, Inc. Pharmaceuticals: MajorHealth Technology Naryx Pharma, Inc. developd products for the treatment of chronic sinusitis. Its products were focused on inhaled, nebulizer, intranasal drug formulations. Its products include Sybryx, which is used for the treatment of chronic sinusitis. The company focused on development of inhaled, nebulized, and intranasal drug formulations. The company was founded in 1999 and was headquartered in Carpinteria, CA. | 18 Jahre |
| Patrick Mahaffy | M | 61 | 9 Jahre | |
| Marc M. P. de Garidel | M | 66 | 15 Jahre | |
| David W. Beier | M | 75 | 10 Jahre | |
| Joseph Hagan | M | 55 | 17 Jahre | |
| Michael Kelly | M | 67 | 14 Jahre | |
| Dennis D. Kim | M | 54 | 3 Jahre | |
| Kathryn Falberg | F | 63 | 6 Jahre | |
| Barbara Dalton | M | 69 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 2 Jahre |
| George Scangos | M | 76 |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | 3 Jahre |
| Kevin Sharer | M | 76 | 20 Jahre | |
| Krisztina Zsebo | M | 68 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 11 Jahre |
| Eran Nadav | M | 55 | 4 Jahre | |
| Ramona Sequeira | F | 58 |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | 8 Jahre |
| Gino Santini | M | 67 | 8 Jahre | |
| Lota Zoth | F | 64 | 7 Jahre | |
| Preston Klassen | M | 55 | 14 Jahre | |
| Madhavan Balachandran | M | 73 | 20 Jahre | |
| Brian Pereira | M | 65 | 7 Jahre | |
| Suzanne McDonald | F | 71 | - | |
| Giovanni Caforio | M | 59 |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | 5 Jahre |
| Carl Johan Kördel | M | 62 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 2 Jahre |
| Jin Long Chen | M | 61 | 4 Jahre | |
| Erin Lavelle | F | 46 | 15 Jahre | |
| Susan Lundeen Smuck | F | 57 | 12 Jahre | |
| Bill Aliski | M | 75 | 11 Jahre | |
| Willard Dere | M | 70 | 11 Jahre | |
| William Ashton | M | 73 | 16 Jahre | |
| Diana McKenzie | F | 59 | 12 Jahre | |
| William P. Sheridan | M | 69 | 5 Jahre | |
| Parvinder S. Hyare | M | - | - | |
| Kathryn Carr Payne | F | - | 4 Jahre | |
| Frans Gustaf Wuite | M | 64 | - | |
| Michael Severino | M | 58 | 10 Jahre | |
| Cynthia Flowers | F | 64 | 5 Jahre | |
| James Daly | M | 62 | 9 Jahre | |
| Dan Omstead | M | 71 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 2 Jahre |
| Barbara H. Deptula | F | 69 | 7 Jahre | |
| Frank Herringer | M | 81 | 15 Jahre | |
| Frank J. Biondi | M | 79 | 15 Jahre | |
| George Morrow | M | 72 | 10 Jahre | |
| Jerry D. Choate | M | 86 | - | |
| David J. Scott | M | 71 | - | |
| Brian M. McNamee | M | 67 | - | |
| Dan Turner | M | 62 | 7 Jahre | |
| Timothy Martin | M | 55 | 3 Jahre | |
| Timothy G. Healey | M | 58 | - | |
| Heather Turner | F | 51 | 8 Jahre | |
| Dominique Monnet | M | 65 | 11 Jahre | |
| Robert Hugin | M | 69 |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | 2 Jahre |
| Frederick Gluck | M | 88 | 13 Jahre | |
| Davey Scoon | M | 78 | 14 Jahre | |
| David Baltimore | M | 86 | 21 Jahre | |
| Gil Omenn | M | 83 | 27 Jahre | |
| Judith C. Pelham | F | 78 | 22 Jahre | |
| James Sulat | M | 73 | 6 Jahre | |
| Brian H. Dovey | M | 83 | 14 Jahre | |
| Joseph Lacob | M | 68 | 8 Jahre | |
| Louis C. Bock | M | 59 | 13 Jahre | |
| J. Reason | M | 83 | 12 Jahre | |
| Clay Siegall | M | 63 | 7 Jahre | |
| Michael Powell | M | 69 | 8 Jahre | |
| Leonard Schaeffer | M | 78 | 9 Jahre | |
| Todd Foley | M | 52 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | 2 Jahre |
| Patricia A. Turney | F | 57 | 23 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 99 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael Narachi
- Persönliches Netzwerk
